

PCB and hydroxy PCB congeners in the blood of patients with Yusho PCB poisoning

Yoshito Masuda¹, Koichi Haraguchi¹

¹Daiichi College of Pharmaceutical Sciences, Fukuoka

Introduction

Rice oil polychlorinated biphenyl (PCB) poisoning called Yusho occurred in Fukuoka and Nagasaki Prefectures, Japan, in 1968. Patients have been suffering from various hormone affected symptoms retaining some persistent PCB and polychlorinated dibenzofuran (PCDF) congeners in the body for more than 35 years¹. In the body of Yusho patients, highly accumulated PCBs and PCDFs have gradually decreased to or less than 2.3 ppm and 0.6 ppb in lipid of blood, respectively, during more than 30 years. Present levels of PCBs and PCDFs in the blood are still several times higher than those of control persons². The particular patterns of concentrations of PCB congeners, namely relatively high concentrations of 2,3,3',4,4',5-hexaCB (PCB156) and low concentrations of 2,3',4,4',5-pentaCB (PCB118), have kept in the blood of patients for the most part of lifetime. PCB metabolites, hydroxy (HO-) PCBs and methylsulfone (MeSO₂-) PCBs have been identified in the human blood and tissues³. HO-PCBs were identified in the blood at levels of 2 to 10 times less than those of PCBs^{4,5}. Sandau et al⁶ identified HO-PCBs and pentachlorophenol (PCP) in umbilical cord plasma of neonate in Quebec, Canada and suggested that PCP and HO-PCBs are possibly altering thyroid hormone status in newborn. We analyzed PCBs, HO-PCBs and MeSO₂-PCBs in the blood of Yusho patients for investigating the possible relations to health effects in Yusho patients..

Materials and methods

Blood sample: Blood samples from Yusho patients were collected at annual health examination in Fukuoka from 1999 to 2003 and kept frozen until analysis. Control bloods were sampled from students and instructors at Daiichi college of pharmaceutical sciences in 1993-1997.

Analysis of blood for PCBs, HO-PCBs and MeSO₂-PCBs : Blood sample 5-10 g was added with internal standards of 6 ¹³C labeled PCBs, namely 3,3',4,4'-tetraCB (PCB77), 2,2',4,5,5'-pentaCB (PCB101), PCB118, 3,3',4,4',5-pentaCB (PCB126), 2,2',4,4',5,5'-hexaCB (PCB153) and PCB156 5 ng, ¹³C labeled 4'-HO-2,2',3,3',4,5,5'-heptaCB (4'HO-PCB172), 4-HO-2,2',3,4',5,5',6-heptaCB (4HO-PCB187) and PCP 5 ng and 4'-Me-5'-MeSO₂-2,3,3',4,5-pentaCB 25 ng, ethanol 10 ml and 2M HCl 10 ml. The mixture was extracted with hexane +

diethyl ether (7 : 3) 10 ml three times. The hexane layers were combined and washed with water and evaporated to dryness, remaining fatty residue being weighed. The residue was dissolved in hexane 10 ml and extracted with 0.5 M KOH/ethanol + water (1 : 1) 5 ml twice (HO-PCB fraction). The hexane solution was chromatographed on silica gel (1 g) column, eluting with hexane 30 ml (PCB fraction) and successively eluting with dichloromethane 30 ml (MeSO₂-PCB fraction). The PCB fraction was concentrated to 0.1 ml and injected to gas chromatograph/mass spectrometry (GC/MS, Shimadzu QP5000) for analysis of PCB congeners, hexachlorobenzene (HCB) and 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE). The HO-PCB fraction was acidified with 2M HCl and extracted with hexane + diethyl ether (4 : 1) 5 ml three times. The hexane layers were combined, concentrated to 1 ml and methylated with diazomethane. The methoxy-PCB solution was fractionated on a multi layer column of sulfuric acid/silica gel (1 g) and silica gel (0.5 g), eluting with dichloromethane 10 ml. The dichloromethane solution was evaporated to dryness and dissolved in hexane 2 ml. The hexane solution was fractionated on silica gel (1g) column, eluting with hexane 30 ml. The hexane eluate was concentrated to 0.1 ml and injected to GC/MS for HO-PCBs and PCP. The MeSO₂-PCB fraction was evaporated and dissolved in hexane, which was partitioned with concentrated sulfuric acid 1 g twice. The sulfuric acid layer was diluted with the same amount of water and back extracted with hexane. The hexane extract was fractionated on silica gel (1 g) column eluting with dichloromethane + hexane (1 : 1). The eluate was concentrated to 0.1 ml and analyzed for MeSO₂-PCBs.

Results and discussion

Concentrations of PCBs, HCB, DDE HO-PCBs and PCP in whole blood of Yusho patients and control persons are shown in Table 1. Their ages, fat contents of blood samples and their concentration ratios of Yusho/control are also displayed in Table 1. HO-PCBs and PCP were first quantified in the blood of Yusho patients and the concentrations were about 1/7 and 1/5, respectively, of the total PCB concentrations in the blood. The concentration ratios of HO-PCBs/total PCBs are comparable to the ratios in the blood of Canadians⁴, Latvians and Swedish⁵, which reported to be in the range from 1/10 to 1/2. The concentration ratios of PCP/total PCBs were more variable from 1/9 to 2/1 in these persons. The ratio of Yusho/Control concentrations in PCB156 is 8.35 and the highest among the congeners in Table 1. The concentrations of PCB118, 2,3,3',4,4'-pentaCB (PCB105) and PCP in Yusho patients were however lower than those of control persons. These characteristic differences by the PCB congeners have been observed in Yusho patients for more than 30 years and used as one of the characteristic signs for diagnosing Yusho. HCB was probably metabolized to PCP in the human body, and the PCP concentrations were however 5 to 10 times higher than the HCB concentrations. PCP is probably more retainable in the human blood than HCB. In Yusho patients, aromatic hydrocarbon hydroxylase (AHH) might have been strongly induced by the toxic congeners such as 2,3,4,7,8-pentaCDF, PCB156 and others, and the induced AHH has been possibly accelerating the metabolism of some retainable and slowly labile PCBs such as PCB118 and PCB105 as well as PCP. Their concentrations are eventually lowered in the body of Yusho patients and their levels of thyroxine and estradiol may have been simultaneously disturbed.

Table 2 lists the correlation coefficients between the pairs of concentrations of the PCBs, HO-PCBs and pesticides in the blood of Yusho patients ($n = 36$). Very high correlation coefficients are observed between the concentrations of PCB153, PCB138, PCB 156 and 4HO-CB187. DDE has high correlation coefficients with PCB138 or PCB156 but low correlation coefficients with 4HO-CB146 or 4HO-CB187. HCB and PCP however do not have significant correlations with any other congeners in the Table 2. Interestingly, age shows significant positive correlations ($p < 0.05$) with the concentrations of PCB153, PCB138, DDE and 4HO-CB146, suggesting their accumulative retention in the body during long human life.

Table 1: Concentrations of PCBs, pesticides and HO-PCBs in the blood of Yusho patients and control persons and their ratios

		Number detected	Concentrations, ppb in whole blood					Ratio Yusho/Co nt
			Mean	SD	Media n	Min	Max	
Age	Yusho		66.4	9.9	68.0	40.5	84.5	3.08
	Control		39.0	21.2	22.1	20.7	62.0	
Lipid (%)	Yusho	36	0.229	0.069	0.213	0.129	0.362	1.81
	Control	9	0.130	0.068	0.118	0.033	0.279	
PCB 118	Yusho	36	0.078	0.046	0.063	0.000	0.208	0.77
	Control	9	0.109	0.063	0.081	0.037	0.197	
PCB 153	Yusho	36	0.659	0.330	0.583	0.024	1.921	2.62
	Control	9	0.340	0.226	0.223	0.104	0.765	
PCB 105	Yusho	34	0.032	0.035	0.019	0.004	0.158	0.47
	Control	9	0.041	0.025	0.040	0.010	0.084	
PCB 138	Yusho	36	0.496	0.352	0.373	0.008	1.973	3.75
	Control	9	0.174	0.124	0.100	0.051	0.405	
PCB 182	Yusho	36	0.101	0.051	0.094	0.165	0.245	1.46
	Control	8	0.073	0.052	0.064	0.017	0.159	

BODY BURDENS AND DIETARY INTAKE

PCB 156	Yusho	36	0.278	0.201	0.225	0.028	1.120	8.35
	Control	9	0.029	0.018	0.027	0.008	0.051	
4								
PCB 180	Yusho	36	0.433	0.224	0.406	0.000	1.293	4.49
	Control	9	0.163	0.143	0.090	0.046	0.422	
0								
Total PCBs	Yusho	36	2.793	1.474	2.460	0.634	8.740	3.19
	Control	9	1.203	0.750	0.771	0.418	2.510	
HCB	Yusho	36	0.105	0.057	0.101	0.007	0.227	1.09
	Control	9	0.100	0.052	0.093	0.038	0.187	
9								
DDE	Yusho	36	2.998	1.657	2.663	0.059	6.731	1.84
	Control	9	2.339	1.772	1.447	0.385	5.728	
6								
4HO-PCB 146	Yusho	35	0.197	0.130	0.165	0.061	0.778	2.12
	Control	8	0.089	0.048	0.078	0.036	0.155	
4HO-PCB 187	Yusho	35	0.206	0.126	0.177	0.057	0.660	1.51
	Control	9	0.145	0.072	0.117	0.045	0.251	
PCP	Yusho	34	0.562	0.385	0.444	0.186	2.314	0.64
	Control	8	0.979	0.701	0.690	0.335	2.061	
MeSO ₂ - PCB	Yusho	0	Not detected (< 0.5)					
	Control	0	Not detected (< 0.2)					

Boldface : Yusho patients,

PCB138: 2,2',3,4,4',5'-hexaCB, PCB182: 2,2',3,4,4',5',6-heptaCB,

PCB180: 2,2',3,4,4',5,5'-heptaCB, 4HO-PCB146: 4-HO-2,2',3,4',5,5'-hexaCB.

Table 2: Correlation coefficients between the concentrations of PCBs, pesticides and HO-PCBs in the blood of Yusho patients (n = 36) and their ages

	Age	PCB 118	PCB 153	PCB 138	PCB 156	HCB	DDE	4OH- PCB 146	4OH- PCB 187	PCP
Age	1									
PCB118	<u>0.268</u>	1								
PCB153	0.400	0.497	1							
PCB138	0.361	0.481	0.949	1						
PCB156	<u>0.270</u>	<u>0.251</u>	0.742	0.760	1					
HCB	<u>0.211</u>	<u>-0.019</u>	<u>0.053</u>	<u>0.186</u>	<u>0.277</u>	1				
DDE	0.473	0.426	0.715	0.770	<u>0.280</u>	<u>0.143</u>	1			
4HO-CB146	0.370	<u>0.086</u>	0.562	0.430	0.591	<u>-0.013</u>	<u>0.093</u>	1		
4HO-CB187	<u>0.269</u>	0.349	0.410	<u>0.249</u>	0.334	<u>-0.233</u>	<u>0.016</u>	0.555	1	
PCP	<u>-0.003</u>	<u>0.135</u>	<u>-0.048</u>	<u>0.043</u>	<u>0.085</u>	<u>0.319</u>	<u>-0.035</u>	<u>-0.177</u>	<u>0.138</u>	1

Boldface > 0.525 : p < 0.001, Lightface > 0.329 : p < 0.05, Underline < 0.329 : not significant.(p > 0.05)

Acknowledgements

This investigation was supported by the grant from Ministry of Health, Labor and Welfare. Some HO-PCB standards were donated from Professor Bergman, Stockholm University.

References

1. Masuda Y. (1996) in: YUSHO (Kuratsune, M, et al Ed), pp 47-80, Kyushu University Press,
2. Masuda, Y. (2001) Chemosphere 43, 925-930
- 3 Letcher, R.J. Klasson-Wehler, E. Ake Bergman, A. (2000) The Handbook of Environmental Chemistry Vol 3 Part K New Types of Persistent Halogenated Compounds ed. by Paasivirta J., pp 315-359.
4. Sandau, CD, Ayotte P, Dewailly E, Duffe J and Norstrom, RJ, (2000). Environ Health Perspect.108, 611-6.
5. Sjödin, A, Hagmar, L., Klasson-Wehler, E., Björk, J., Bergman A., (2002). Environ Health Perspect.108, 1035-41.
6. Sandau CD, Ayotte P, Dewailly E, Duffe J and Norstrom, RJ, (2002) Environ Health Perspect 110, 411-7.